Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ГБОУ ВПО Ставропольский государственный медицинский университет Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310; 2Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева; 3ООО «Пфайзер». 123317, Россия, Москва, Пресненская наб., д. 10, БЦ «Башня на Набережной» (Блок С)
Список исп. литературыСкрыть список 1. Gardner DM et al. Evidence review and clinical guidance for the use of ziprasidone in Canada. Ann Gen Psychiatry 2013; 12 (1): 1. 2. Nemeroff CB et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr 2005; 10 (11 Suppl. 17): 1–20. 3. Auclair AL et al. Actions of Novel Antipsychotic Agents on Apomorphine-Induced PPI Disruption: Influence of Combined Serotonin 5-HT1A Receptor Activation and Dopamine D2 Receptor Blockade. Neuropsychopharmacology 2006; 31 (9): 1900–9. 4. Mansbach RS, Carver J, Zorn SH. Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone. Pharmacol Biochem Behav 2001; 69 (3–4): 535–42. 5. Salazar J et al. Switch to ziprazidone treatment is associated with changes in MMN amplitude: A case report. Progress in Neuro-Psy-chopharmacology and Biological Psychiatry 2009; 33 (3): 573–4. 6. Lacroix LP et al. 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse. Wiley Subscription Services, Inc., A Wiley Company 2004; 51 (2): 158–64. 7. Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res 2008; 172: 199–212. 8. Newman-Tancredi A, Kleven MS. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl) 2011; 216 (4): 451–73. 9. Mestre TA, Zurowski M, Fox SH. 5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders. Exp Opin Investig Drugs 2013; 22 (4): 411–21. 10. Rollema H et al. 5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psy-chiatry 2000; 48 (3): 229–37. 11. Westerink BHC et al. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol 2001; 412 (2): 127–38. 12. Schneider MR et al. The effects of ziprasidone on prefrontal and amygdalar activation in manic youth with bipolar disorder. Isr J Psychiatry Relat Sci 2012; 49 (2): 112–20. 13. Geerts H et al. Understanding responder neurobiology in schizophrenia using a quantitative systems pharmacology model: Application to iloperidone. J Psychopharmacol 2015; 29 (4): 372–82. 14. Meier A et al. Ziprasidone decreases cortisol excretion in healthy subjects. Br J Clin Pharmacol 2005; 60 (3): 330–6. 15. Walder DJ, Walker EF, Lewine RJ. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol Psychiatry 2001/01/04 ed. 2000; 48 (12): 1121–32. 16. Halari R et al. The relationship of sex hormones and cortisol with cognitive functioning in Schizophrenia. J Psychopharmacol 2004/09/11 ed. 2004; 18 (3): 366–74. 17. Park SW et al. Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA BDNF expression in the hippocampus and neocortex of rats. J Psychiatr Res 2009; 43 (3): 274–81. 18. Kaengkan P et al. Administration of mesenchymal stem cells and ziprasidone enhanced amelioration of ischemic brain damage in rats. Mol Cells Korean Soc Mol Cell Biol 2013; 36 (6): 534–41. 19. Benninghoff J et al. Ziprasidone – not haloperidol-induces more de-novo neurogenesis of adult neural stem cells derived from murine hippocampus. Pharmacopsychiatry. C Georg Thieme Verlag KG 2013; 46 (1): 10–5. 20. Marcus MM et al. Adjunctive a2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int J Neuropsychopharmacol 2010; 13 (7): 891–903. 21. Imaki J et al. Therapeutic potential of a2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders. Neurosci Letters 2009; 454 (2): 143–47. 22. Weber M et al. Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44. Pharmacol Biochem Behav NIH Public Access 2009; 93 (2): 141–7. 23. Réus GZ et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 2015; 300: 141–54. 24. Bian Q et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-g. Prog NeuroPsychopharmacology Biol Psychiatry 2008; 32 (1): 42–8. 25. Komossa K et al. Ziprasidone versus other atypical antipsychotics for schizophrenia (Review). Cochrane Database Syst Rev 2009; 4. 26. Lieberman JA et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353 (12): 1209–23. 27. Leucht S et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet (London, England) 2013; 382 (9896): 951–62. 28. Zhao YJ et al. Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials. Br J Psychiatry Open 2016; 2 (1): 59–66. 29. Potkin SG et al. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. Int J Neuropsychopharmacol. The Oxford University Press 2009; 12 (9): 233. 30. Keck P et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998; 140 (2): 173–84. 31. Daniel DG et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20 (5): 491–505. 32. Goff DC et al. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J Clin Psychopharmacol 2013; 33 (4): 485–90. 33. Simpson GM et al. Six-Month, Blinded, Multicenter Continuation Study of Ziprasidone Versus Olanzapine in Schizophrenia. Am J Psychiatry 2005; 162 (8): 1535–8. 34. Морозов П.В. Зелдокс (зипрасидон) – новый атипичный нейролептик. Психиатрия и психофармакотерапия. 2005; 7 (5): 264–8. / Morozov P.V. Zeldoks (ziprasidon) – novyi atipichnyi neiroleptik. Psichyatry and Psychopharmacotherapy. 2005; 7 (5): 264–8. [in Russian] 35. Citrome L et al. Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: A post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophr Res Elsevier 2009; 111 (1-3): 39–45. 36. Капилетти С.Г. Зипрасидон – новый эффективный и безопасный антипсихотик (на правах рекламы). Соврем. терапия психических расстройств. 2007; 3: 64—71. / Kapiletti S.G. Ziprasidon – novyi effektivnyi i bezopasnyi antipsikhotik (na pravakh reklamy). Sovrem. terapiia psikhicheskikh rasstroistv. 2007; 3: 64–71. [in Russian] 37. Joyce AT et al. Effect of initial ziprasidone dose on length of therapy in schizophrenia. Schizophr Res 2006; 83 (2–3): 285–92. 38. Daniel DG et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001; 155 (2): 128–34. 39. Johnsen E et al. Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study. BMC Psychiatry 2013; 13: 241–51. 40. Nicolson SE, Nemeroff CB. Ziprasidone in the treatment of mania in bipolar disorder. Neuropsychiatr Dis Treat Dove Press 2007; 3 (6): 823–34. 41. Millan MJ et al. Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol 2014; 24 (5): 645–92. 42. Olié J-P et al. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int Clin Psychopharmacol 2006; 21 (3): 143–51. Полный список литературы можно посмотреть на нашем сайте в Интернете: www.con-med.ru 43. Stahl SM et al. A Post Hoc Analysis of Negative Symptoms and Psychosocial Function in Patients With Schizophrenia. J Clin Psychopharmacol 2010; 30 (4): 425–30. 44. Harvey PD, Bowie CR. Improving cognition in schizophrenia: Pharmacological and cognitive remediation approaches. Minerva Psichiatrica 2013; 54 (1): 1–13. 45. Van Veelen NMJ et al. Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia. Schizophr Res 2010; 120 (1–3): 191–8. 46. Chen X et al. A paired case-control comparison of ziprasidone on visual sustained attention and visual selective attention in patients with paranoid schizophrenia. Eur Rev Med Pharmacol Sci. 2015; 19: 2952–6. 47. Harvey PD. Ziprasidone and cognition: the evolving story. J Clin Psychiatry 2003; 64 (Suppl. 1): 33–9. 48. Gibel A, Ritsner MS. Neurocognitive Effects of Ziprasidone and Related Factors in Patients With Chronic Schizophrenia Undergoing Usual Care. Clin Neuropharmacol 2008; 31 (4): 204–20. 49. Harvey PD et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 2004; 66 (2–3): 101–13. 50. Muscatello MR et al. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2014; 34 (1): 129–33. 51. Gutiérrez Fraile M, de la Gándara Martín JJ, Bobes García J. Switching to ziprasidone in the clinical practice setting: an open-label study. Int J Psychiatry Med 2013; 45 (2): 125–42. 52. Loebel A, Siu C, Romano S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr 2004; 9 (5): 357–64. 53. Pijnenborg GHM et al. Differential effects of antipsychotic drugs on insight in first episode schizophrenia: Data from the European First-Episode Schizophrenia Trial (EUFEST). Eur Neuropsychopharmacol 2015; 25 (6): 808–16. 54. Malhotra AK et al. Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity? Schizophr Res 2006; 8 (1-3): 181–4. 55. Désaméricq G et al. Long-term neurocognitive effects of antipsychotics in schizophrenia: A network meta-analysis. Eur J Clin Pharmacol 2014; 70 (2): 127–34. 56. Gitlin M, Frye MA. Maintenance therapies in bipolar disorders. Bipolar Disord Blackwell Publishing Ltd. 2012; 14 (s2): 51–65. 57. Taylor DM et al. Comparative efficacy and acceptability of drug treatments for bipolar depression: A multiple-treatments meta-analysis. Acta Psychiatr Scand 2014; 130 (60): 452–69. 58. Bowden CL. The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder. Neuropsychiatr Dis Treat 2011; 7: 87–92. 59. Rosa AR et al. Ziprasidone in the treatment of affective disorders: a review. CNS Neurosci Ther 2008; 14 (4): 278–86. 60. Dunner DL et al. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry 2007; 68 (7): 1071–7. 61. Kjelby E et al. Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial. BMC Psychiatry 2011; 11 (1): 145. 62. Patkar A et al. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One 2012; 7 (4). 63. Fonseka TM, Richter MA, Müller DJ. Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature. Curr Psychiatry Rep 2014; 16 (11): 510. 64. Juven-Wetzler A et al. Treatment with Ziprasidone for schizophrenia patients with OCD. Eur Neuropsychopharmacol 2014; 24 (9): 1454–62. 65. Wilner KD et al. The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J Clin Psychopharmacol 2002; 22 (2): 206–10. 66. Ventriglio A et al. Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Front Neurosci 2015; 9: 297. 67. National Institute of Health and Clinical Excellence. No Title. Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014. 2014; p. 74–80. 68. De Hert M et al. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009; 8 (1): 15–22. 69. De Hert M et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10 (1): 52–77. 70. Tek C et al. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry 2016; 10 (3): 193–202. 71. Cooper SJ et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 2016; p. 1–32. 72. Stroup TS et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163 (4): 611–22. 73. Zhang H et al. Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia. Neuropsychiatr. Dis Treat 2011; 7: 77–85. 74. Kaye NS. Ziprasidone augmentation of clozapine in 11 patients. J Clin Psychiatry Physicians Postgraduate Press, Inc. 2003; 64 (2): 215–6.